Telix Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 6:11 AM
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
961.37
Dividend yield
0.00%
Beta
-
Market cap
-
Enterprise value
-
Company profile
| Primary activities | Development and commercialising molecularly targeted radiation products for the treatment of cancer. |
|---|---|
| Industry / Sector | Biotechnology / Healthcare |
| Website | https://telixpharma.com |
| Mailing address | 55 Flemington Road Suite 401 North Melbourne VIC 3051 Australia |
| Phone / Fax | 61 3 3093 3897 / |
| Share registry | LINK MARKET SERVICES LIMITED |
Dividends
More: Telix Pharmaceuticals Dividend history, yield and payout ratio
Dividend yield
0.00%
Dividend amount
$0.00
Payout ratio
0.00%
Telix Pharmaceuticals paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.TLX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
TLX's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of Aug 2022, following are the company executives and directors listed on Telix Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, Group MD, CEO & Exec. Director | 46 | 528.83k |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor & Director | 65.85k | |
| Mr. Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer | 56 | |
| Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist | ||
| Ms. Kyahn Williamson | Sr. VP of Corp. Communications & Investor Relations | ||
| Mr. Jonathan Barlow B.Sc., L.L.B. | Chief Bus. Devel. Officer & Group Gen. Counsel | ||
| Ms. Amanda Griffin | Communications Mang. | ||
| Mr. Christian Davis | VP Sales and Marketing, EMEA | ||
| Ms. Helen Hovenga B.A., M.B.A. | Global Chief People Officer | ||
| Dr. Jyoti Arora BappSc(Hons), Ph.D. | Chief Operating Officer of APAC |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-394.64%
Return on assets
-41.11%
Return on equity
-155.07%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Telix Pharmaceuticals is and its enterprise value is .
Companies similar to Telix Pharmaceuticals (TLX)
Telix Pharmaceuticals (ASX:TLX) Frequently Asked Questions
1. What is Telix Pharmaceuticals's Stock Symbol?
Telix Pharmaceuticals trades on ASX under the ticker symbol "TLX".
2. What is Telix Pharmaceuticals's stock price today?
One share of TLX stock can currently be purchased for approximately $6.33.
3. How can I contact Telix Pharmaceuticals?
Telix Pharmaceuticals's mailing address is 55 Flemington Road Suite 401 North Melbourne VIC 3051 Australia. The company can be reached via phone at 61 3 3093 3897.
4. What is Telix Pharmaceuticals's official website?
The official website of Telix Pharmaceuticals is https://telixpharma.com.
5. Which share registry manages Telix Pharmaceuticals's stock?
Telix Pharmaceuticals's stock is managed by LINK MARKET SERVICES LIMITED.